Bayer Launches Phase III Study of Devasaban　　

Business Agency, March 5 ( Bayer) announced the launch of phase III clinical trial EINSTEIN CHOICE study to evaluate the role of long-term secondary prophylaxis of symptomatic venous thrombosis (VTE) compared to acetyl salicylic acid (ASA) in the daily two treatments of the new oral anticoagulant drug Delevaschabanstudy will include approximately 2,850 patients from about 250 clinical research centers in 30 countries worldwide, and in patients with deep vein thrombosis and pulmonary embolism who have completed anticoagulant treatment for 6 or 12 months, to evaluate whether the 10mg or 20mg dose regimen in the prevention of the recurrence of lethal or non-lethal symptomatic venous thrombosis is better than 100mg of acetylacidic acid once a day" for patients with unexplained venous thrombosis, if the anticoagulant treatment is terminated after 6 to 12 months, the risk of recurrence within one year is about 10%However, due to the management inconvenience and bleeding concerns, many doctors still terminate warfarin treatment after the patient's six-month treatment period and may convert it to aspirinJeffrey Weitz, professor and vice president of research at McMaster University's Department of Medicine, said"The design of the study is to tell us whether reducing the dose of devashaban from 20 mg per day to 10 mg per day can maintain therapeutic efficacy and reduce the risk of bleeding, and whether both dose levels of Devalsaban are better at reducing the risk of recurrence than aspirin." Therefore, the results of this study may help to establish a parallel relationship between anticoagulant therapy and individual benefit-risk conditions in patients"